Literature DB >> 23225196

Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival.

Francesco Ardito1, Maria Vellone, Alessandra Cassano, Agostino M De Rose, Carmelo Pozzo, Alessandro Coppola, Bruno Federico, Ivo Giovannini, Carlo Barone, Gennaro Nuzzo, Felice Giuliante.   

Abstract

BACKGROUND: Survival with long-term follow-up following liver resection for unresectable colorectal liver metastases (CRLM) downsized by chemotherapy has rarely been reported. The aim of this study was to determine the chance of cure following liver resection for initially unresectable CRLM.
METHODS: Between January 2000 and December 2009, 61 patients underwent hepatectomy for unresectable liver-only CRLM downsized after chemotherapy. Cure was defined as a recurrence-free interval of at least 5 years after primary hepatectomy.
RESULTS: Resectability of CRLM was achieved after a mean number of 11 courses, and 42.6 % of patients underwent liver resection after ≥10 courses. Postoperative mortality was nil, and morbidity rate was 19.7 %. The 5- and 10-year actuarial overall survival rates were 42.6 and 16.0 %. Of 30 patients with a follow-up ≥5 years, 11 were alive, yielding a 5-year actual overall survival rate of 36.7 %, and 7 (23.3 %) were considered cured because they are alive without recurrence. On multivariate analysis, response to chemotherapy was the only independent predictor of both overall and disease-free survival.
CONCLUSIONS: Cure can be achieved in about 23 % of patients resected for initially unresectable CRLM downsized by chemotherapy. Liver resection can be safely performed in selected patients even after multiple courses of chemotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 23225196     DOI: 10.1007/s11605-012-2103-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  26 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

Authors:  Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

3.  Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection.

Authors:  Robbert J de Haas; Dennis A Wicherts; Paola Andreani; Gérard Pascal; Faouzi Saliba; Philippe Ichai; René Adam; Denis Castaing; Daniel Azoulay
Journal:  Ann Surg       Date:  2011-06       Impact factor: 12.969

Review 4.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.

Authors:  Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier
Journal:  Eur J Cancer       Date:  2006-08-10       Impact factor: 9.162

5.  Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.

Authors:  Steven R Alberts; William L Horvath; William C Sternfeld; Richard M Goldberg; Michelle R Mahoney; Shaker R Dakhil; Ralph Levitt; Kendrith Rowland; Suresh Nair; Daniel J Sargent; John H Donohue
Journal:  J Clin Oncol       Date:  2005-10-17       Impact factor: 44.544

Review 6.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

Authors:  Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Journal:  Eur J Cancer       Date:  2007-09-04       Impact factor: 9.162

7.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

9.  Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

Authors:  M Ychou; F Viret; A Kramar; F Desseigne; E Mitry; R Guimbaud; J R Delpero; M Rivoire; F Quénet; G Portier; B Nordlinger
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-28       Impact factor: 3.333

Review 10.  Expanding criteria for resectability of colorectal liver metastases.

Authors:  Timothy M Pawlik; Richard D Schulick; Michael A Choti
Journal:  Oncologist       Date:  2008-01
View more
  14 in total

1.  Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study.

Authors:  Simeon Niyi Babawale; Thomas Mandøe Jensen; Jens Brøndum Frøkjær
Journal:  World J Gastrointest Surg       Date:  2015-03-27

2.  The impact of intraoperative ultrasonography on the management of disappearing colorectal liver metastases.

Authors:  Felice Giuliante; Elena Panettieri; Francesco Ardito
Journal:  Hepat Oncol       Date:  2015-11-06

3.  Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors.

Authors:  Iswanto Sucandy; Susannah Cheek; Benjamin J Golas; Allan Tsung; David A Geller; James W Marsh
Journal:  HPB (Oxford)       Date:  2016-07-09       Impact factor: 3.647

4.  Possibility of repeat surgery for recurrence following two-stage hepatectomy for colorectal liver metastases: impact on patient outcome.

Authors:  Francesco Ardito
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

5.  Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.

Authors:  Linda M Pak; Nancy E Kemeny; Marinela Capanu; Joanne F Chou; Taryn Boucher; Andrea Cercek; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica
Journal:  J Surg Oncol       Date:  2017-11-22       Impact factor: 3.454

6.  Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.

Authors:  So Hyun Kim; Jae Hwang Kim; Sang Hun Jung
Journal:  Int J Colorectal Dis       Date:  2015-06-14       Impact factor: 2.571

7.  Prognostic factors of hepatectomy in initially unresectable colorectal liver metastasis: Indication for conversion therapy.

Authors:  Hiroya Iida; Masaki Kaibori; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Masahiko Kinoshita; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  Mol Clin Oncol       Date:  2018-09-03

8.  Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.

Authors:  Michael I DʼAngelica; Camilo Correa-Gallego; Philip B Paty; Andrea Cercek; Alexandra N Gewirtz; Joanne F Chou; Marinella Capanu; T Peter Kingham; Yuman Fong; Ronald P DeMatteo; Peter J Allen; William R Jarnagin; Nancy Kemeny
Journal:  Ann Surg       Date:  2015-02       Impact factor: 12.969

9.  Additional lymphadenectomy might not improve survival of patients with resectable metastatic colorectal adenocarcinoma of T4 stage, proximal location, poor/undifferentiation, or N3/N4 stages: a large population-based study.

Authors:  Yang-Yang Zhou; Qing-Wei Zhang; Jian Huang; Xia-Lin Yan; Chao Chen; Fan-Fan Xu; Xiao-Jing Du; Rong Jin
Journal:  J Cancer       Date:  2018-06-14       Impact factor: 4.207

10.  FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION.

Authors:  Felipe José Fernandez Coimbra; Heber Salvador de Castro Ribeiro; Márcio Carmona Marques; Paulo Herman; Rubens Chojniak; Antonio Nocchi Kalil; Evanius Garcia Wiermann; Sandro Roberto de Araújo Cavallero; Fabricio Ferreira Coelho; Paulo Henrique de Souza Fernandes; Anderson Arantes Silvestrini; Maria Fernanda Arruda Almeida; Antônio Luis Eiras de Araújo; Marcos Pitombo; Heberton Medeiros Teixeira; Fábio Luiz Waechter; Fábio Gonçalves Ferreira; Alessandro Landskron Diniz; Giuseppe D'Ippolito; Giuseppe D'Ippolito; Maria Dirlei F de Sousa Begnami; Gabriel Prolla; Silvio Márcio Pegoraro Balzan; Thiago Bueno de Oliveira; Luís Arnaldo Szultan; Javier Lendoire; Orlando Jorge Martins Torres
Journal:  Arq Bras Cir Dig       Date:  2015 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.